Sign in Subscribe
Pharmaceutical industry

Molecular Insight Pharmaceuticals Presents Positive Data from Phase 1 Clinical Studies for Trofex and Prostate Cancer Imaging

Strategic Insights

— 2 min read

Molecular Insight Pharmaceuticals has presented positive data from Phase 1 clinical studies comparing its lead molecular imaging candidate, Trofex, with ProstaScint for the diagnosis and monitoring of metastatic prostate cancer. The studies demonstrated that Trofex rapidly detected prostate cancer localized in the prostate bed, soft tissues, and bone within four hours post-injection, whereas ProstaScint required five days and was unable to detect metastatic disease in bone. Trofex's high degree of uptake and retention in prostate cancer cells allows for non-invasive molecular imaging of prostate cancer, offering a potential alternative to traditional imaging methods.

Key Takeaways:

  • Trofex, Molecular Insight's lead molecular imaging candidate, rapidly detected prostate cancer localized in the prostate bed, soft tissues, and bone within four hours post-injection.
  • In comparison, ProstaScint, a radiopharmaceutical for the visualization of metastatic prostate cancer, required five days for optimal imaging and was unable to detect metastatic disease in bone.
  • Trofex binds to prostate-specific membrane antigen (PSMA) with high affinity and specificity, allowing for non-invasive molecular imaging of prostate cancer.
  • Molecular Insight reported that Trofex visualized lesions in the prostate, lymph nodes, and bone at four hours after injection, confirming the viability of targeting PSMA with small molecules for imaging metastatic prostate cancer.
  • ProstaScint required supplementary blood pool imaging for confirmation of lymph node metastases along the normal vasculature.
  • The Company announced the development of an analog of Trofex that carries the therapeutic iodine radionuclide, I-131, creating a molecularly targeted radiotherapeutic that specifically binds PSMA on prostate cancer cells.
  • Preclinical data demonstrated that Molecular Insight's compound, 131I-MIP-1375, was effective at inhibiting, in a dose-related manner, the growth of human PSMA-expressing prostate tumors in a mouse model.
  • The Company plans to advance the development of 131I-MIP-1375 as a targeted radiotherapeutic option in the treatment of prostate cancer.
  • Prostate cancer is the second leading cause of cancer death among men in the United States, with approximately 200,000 new cases diagnosed annually.
  • Molecular Insight Pharmaceuticals has five clinical-stage candidates in development, including Trofex and 131I-MIP-1375.

Statistics:

  • The two completed Phase 1 studies enrolled a total of 13 subjects (7 prostate cancer patients and 6 healthy volunteers).
  • The ongoing Phase 1 study has enrolled 12 patients.
  • 370 MBq of Trofex was administered to patients in the first two studies.
  • Trofex scans were used to estimate organ pharmacokinetics and calculate radiation dosimetry.
  • ProstaScint images were compared with Trofex images and bone scans in the same patient.
  • 131I-MIP-1375 inhibited human PSMA-expressing prostate tumor growth in a dose-related manner in a mouse model.

Sources:

  • Molecular Insight Pharmaceuticals, Inc. press release, October 14, 2010.
  • European Association of Nuclear Medicine Annual Congress presentation, October 14, 2010.
  • American Cancer Society, prostate cancer statistics.
  • Molecular Insight Pharmaceuticals, Inc. website, www.molecularinsight.com.
  • Comtex SmarTrend Alert, October 10, 2010.

Read more